Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTJ1NH)

• Drug Name: L-serine-O-phosphate Drug Info
• Synonyms: Phosphoserine; O-phospho-L-serine; Dexfosfoserine; phosphoserine; 407-41-0; L-O-Phosphoserine; Fosforina; O-Phosphoserine; L-SOP; L-Phosphoserine; PHOSPHONOSERINE; 3-phosphoserine; L-Serine O-phosphate; Dexfosfoserine [INN]; Phosphatidalserine; 3-O-Phosphoserine; H-Ser(PO3H2)-OH; O-phosphono-L-serine; serine, O-phosphono-; (+)-L-Serine dihydrogen phosphate (ester); L-Seryl phosphate; UNII-VI4F0K069V; L-3-Phosphoserine; L-O-Serine phosphate; L-Serinephosphoric acid; H-Ser(PO)-OH; L-2-amino-3-hydroxypropanoic acid 3-phosphate; LSOP; Phosphonoserine

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1] , [2]

• Cross-matching ID:
  PubChem CID: 68841
  ChEBI ID: CHEBI:15811
  CAS Number: CAS 407-41-0
  TTD Drug ID: DMTJ1NH

Molecule-Related Drug Atlas

Drug(s) Targeting Rhodopsin (RHO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[1]
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[1]
Phosphonothreonine	DMTFHPI	Discovery agent	N.A.	Investigative	[1]
Beta-D-Mannose	DMHIG9K	Discovery agent	N.A.	Investigative	[1]
Hexadecanoic acid	DMWUXDZ	Discovery agent	N.A.	Investigative	[1]
NSC-88915	DM9WIHJ	Solid tumour/cancer	2A00-2F9Z	Investigative	[7]
Lauryl Dimethylamine-N-Oxide	DM3W2OE	Discovery agent	N.A.	Investigative	[1]
B-2-Octylglucoside	DMEGX8H	Discovery agent	N.A.	Investigative	[1]
(Hydroxyethyloxy)Tri(Ethyloxy)Octane	DMY6FUD	Discovery agent	N.A.	Investigative	[1]
B-Nonylglucoside	DM48VJR	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting Phosphoinositide dependent protein kinase-1 (PDPK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AR-12	DM4RK6P	Lymphoma	2A80-2A86	Phase 1	[9]
PMID20005102C1	DMMESBW	Discovery agent	N.A.	Investigative	[10]
BX-912	DMZA45C	Discovery agent	N.A.	Investigative	[11]
BX-795	DMRIMLJ	Discovery agent	N.A.	Investigative	[11]
PHT-427	DMI96Y3	Discovery agent	N.A.	Investigative	[12]
PF-5177624	DMUOFT0	Solid tumour/cancer	2A00-2F9Z	Investigative	[13]
GSK-2334470	DM3BI7R	Solid tumour/cancer	2A00-2F9Z	Investigative	[14]

Drug(s) Targeting Protein kinase C theta (PRKCQ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sotrastaurin acetate	DME53YS	Renal transplantation	NE84	Phase 2	[15]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[16]
LY-317644	DMM20PI	N. A.	N. A.	Terminated	[17]
CDE-6960	DMA0DKI	Inflammation	1A00-CA43.1	Terminated	[18]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[19]
LY-326449	DMN53M4	Discovery agent	N.A.	Investigative	[20]
[2,2':5',2'']Terthiophen-4-yl-methanol	DMRQC1F	Discovery agent	N.A.	Investigative	[21]
4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol	DM8IYG1	Discovery agent	N.A.	Investigative	[22]
2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile	DMNGW1A	Discovery agent	N.A.	Investigative	[22]
[2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde	DMWDNLI	Discovery agent	N.A.	Investigative	[21]

Drug(s) Targeting Metabotropic glutamate receptor 6 (mGluR6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-CCG-I	DMPZ8XH	Discovery agent	N.A.	Investigative	[23]
(1S,3R)-ACPD	DM5DOAF	Discovery agent	N.A.	Investigative	[24]
MAP4	DMUCE93	Discovery agent	N.A.	Investigative	[25]
MPPG	DMJHQ9T	Discovery agent	N.A.	Investigative	[24]
[3H]LY341495	DMGX0Y8	Discovery agent	N.A.	Investigative	[5]
alpha-methylserine-O-phosphate	DMCIH1X	Discovery agent	N.A.	Investigative	[25]
L-AP4	DMPJFGI	Discovery agent	N.A.	Investigative	[4]
PHCCC	DMNJY79	Discovery agent	N.A.	Investigative	[26]
LSP4-2022	DMBWHGP	Discovery agent	N.A.	Investigative	[27]
(S)-3,4-DCPG	DMG5BUA	Discovery agent	N.A.	Investigative	[28]

Drug(s) Targeting Metabotropic glutamate receptor 7 (mGluR7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
[3H]quisqualate	DMDQBTX	Discovery agent	N.A.	Investigative	[29]
L-CCG-I	DMPZ8XH	Discovery agent	N.A.	Investigative	[5]
(1S,3R)-ACPD	DM5DOAF	Discovery agent	N.A.	Investigative	[5]
(+)-MCPG	DMG5QJB	Discovery agent	N.A.	Investigative	[5]
MAP4	DMUCE93	Discovery agent	N.A.	Investigative	[5]
MPPG	DMJHQ9T	Discovery agent	N.A.	Investigative	[5]
[3H]LY341495	DMGX0Y8	Discovery agent	N.A.	Investigative	[5]
alpha-methylserine-O-phosphate	DMCIH1X	Discovery agent	N.A.	Investigative	[5]
L-AP4	DMPJFGI	Discovery agent	N.A.	Investigative	[5]
LSP4-2022	DMBWHGP	Discovery agent	N.A.	Investigative	[27]

Drug(s) Targeting Metabotropic glutamate receptor 8 (mGluR8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
[3H]quisqualate	DMDQBTX	Discovery agent	N.A.	Investigative	[29]
L-CCG-I	DMPZ8XH	Discovery agent	N.A.	Investigative	[6]
(1S,3R)-ACPD	DM5DOAF	Discovery agent	N.A.	Investigative	[30]
MAP4	DMUCE93	Discovery agent	N.A.	Investigative	[31]
MPPG	DMJHQ9T	Discovery agent	N.A.	Investigative	[30]
alpha-methylserine-O-phosphate	DMCIH1X	Discovery agent	N.A.	Investigative	[25]
L-AP4	DMPJFGI	Discovery agent	N.A.	Investigative	[6]
(S)-3,4-DCPG	DMG5BUA	Discovery agent	N.A.	Investigative	[28]
ACPT-I	DM264XN	Discovery agent	N.A.	Investigative	[32]
CPPG	DMVHX5T	Discovery agent	N.A.	Investigative	[31]

Drug(s) Targeting Pseudomonas Phosphomannomutase/phosphoglucomutase (Pseudo algC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alpha-D-Glucose-6-Phosphate	DMR0EVN	Discovery agent	N.A.	Investigative	[1]
D-mannose 1-phosphate	DM7O1IW	Discovery agent	N.A.	Investigative	[1]
Alpha-D-Mannose-6-Phosphate	DM3NCM1	Discovery agent	N.A.	Investigative	[1]
Alpha-D-Glucose-1-Phosphate	DMU36HT	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Glycogen phosphorylase muscle form (GP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
URSOLIC ACID	DM4SOAW	Metabolic syndrome x	5C50-5D2Z	Phase 2	[33]
JTT-651	DMGP42Q	Type-2 diabetes	5A11	Discontinued in Phase 1	[34]
Beta-D-Glucose	DM5IHYP	Discovery agent	N.A.	Investigative	[1]
Indirubin-5-sulfonate	DM08VHZ	Discovery agent	N.A.	Investigative	[1]
Inosinic Acid	DMLR86H	Discovery agent	N.A.	Investigative	[1]
Alpha-D-Glucose-6-Phosphate	DMR0EVN	Discovery agent	N.A.	Investigative	[1]
N'-Pyridoxyl-Lysine-5'-Monophosphate	DM3ZHBO	Discovery agent	N.A.	Investigative	[1]
OLEANOLIC_ACID	DMWDMJ3	Discovery agent	N.A.	Investigative	[35]
Oleanonic acid	DMYPJC3	Discovery agent	N.A.	Investigative	[35]
Nojirimycine Tetrazole	DMYZRTB	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting Metabotropic glutamate receptor 4 (mGluR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DT-1687	DMU2GP4	Parkinson disease	8A00.0	Phase 2	[36]
L-CCG-I	DMPZ8XH	Discovery agent	N.A.	Investigative	[37]
MAP4	DMUCE93	Discovery agent	N.A.	Investigative	[38]
MPPG	DMJHQ9T	Discovery agent	N.A.	Investigative	[38]
L-AP4	DMPJFGI	Discovery agent	N.A.	Investigative	[38]
PHCCC	DMNJY79	Discovery agent	N.A.	Investigative	[39]
2-methyl-6-(phenylethynyl)pyridine	DMVQK4Y	Discovery agent	N.A.	Investigative	[40]
LSP4-2022	DMBWHGP	Discovery agent	N.A.	Investigative	[27]
(S)-3,4-DCPG	DMG5BUA	Discovery agent	N.A.	Investigative	[28]
ACPT-I	DM264XN	Discovery agent	N.A.	Investigative	[41]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glycogen phosphorylase muscle form (GP)	TTZHY6R	PYGM_HUMAN	Inhibitor	[1]
Metabotropic glutamate receptor 4 (mGluR4)	TTICZ1O	GRM4_HUMAN	Agonist	[3]
Metabotropic glutamate receptor 6 (mGluR6)	TTWRP2F	GRM6_HUMAN	Agonist	[4]
Metabotropic glutamate receptor 7 (mGluR7)	TT0I76D	GRM7_HUMAN	Agonist	[5]
Metabotropic glutamate receptor 8 (mGluR8)	TT0IFKL	GRM8_HUMAN	Agonist	[6]
Phosphoinositide dependent protein kinase-1 (PDPK1)	TT9QBI6	PDPK1_HUMAN	Inhibitor	[1]
Protein kinase C theta (PRKCQ)	TT8QL1J	KPCT_HUMAN	Inhibitor	[1]
Pseudomonas Phosphomannomutase/phosphoglucomutase (Pseudo algC)	TTLP3GX	ALGC_PSEAE	Inhibitor	[1]
Rhodopsin (RHO)	TTH0KSX	OPSD_HUMAN	Inhibitor	[1]

References

• [1] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1411).
• [3] Serine-O-phosphate has affinity for type IV, but not type I, metabotropic glutamate receptor. Neuroreport. 1993 Sep;4(9):1099-101.
• [4] Cloning, distribution and functional expression of the human mGlu6 metabotropic glutamate receptor. Neuropharmacology. 1997 Feb;36(2):145-52.
• [5] Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54.
• [6] Cloning and functional expression of alternative spliced variants of the human metabotropic glutamate receptor 8. Brain Res Mol Brain Res. 1999 Apr 20;67(2):201-10.
• [7] Modulating G-protein coupled receptor/G-protein signal transduction by small molecules suggested by virtual screening. J Med Chem. 2008 Sep 11;51(17):5297-303.
• [8] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [9] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [10] 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83.
• [11] Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
• [12] Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther. 2010 Mar;9(3):706-17.
• [13] Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells. PLoS One. 2012;7(10):e48402.
• [14] Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma. Oncogene. 2014 Aug 21;33(34):4330-9.
• [15] Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
• [16] Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
• [17] Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
• [18] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025002)
• [19] Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
• [20] (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71.
• [21] Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
• [22] Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
• [23] Comparative effect of L-CCG-I, DCG-IV and gamma-carboxy-L-glutamate on all cloned metabotropic glutamate receptor subtypes. Neuropharmacology. 1998 Aug;37(8):1043-51.
• [24] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 294).
• [25] The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Curr Drug Targets CNS Neurol Disord. 2002 Jun;1(3):297-317.
• [26] The mGlu(4) receptor allosteric modulator N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide acts as a direct agonist at mGlu(6) receptors. Eur J Pharmacol. 2008 Jul 28;589(1-3):49-52.
• [27] A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential. FASEB J. 2012 Apr;26(4):1682-93.
• [28] (S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord. Neuropharmacology. 2001 Mar;40(3):311-8.
• [29] Excitatory amino acid receptor ligands: resolution, absolute stereochemistry, and enantiopharmacology of 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)... J Med Chem. 1998 Mar 12;41(6):930-9.
• [30] Group III human metabotropic glutamate receptors 4, 7 and 8: molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells. Brain Res Mol Brain Res. 1998 Jan;53(1-2):88-97.
• [31] Constraints on proper folding of the amino terminal domains of group III metabotropic glutamate receptors. Brain Res Mol Brain Res. 2000 Mar 10;76(1):180-90.
• [32] Pharmacological characterization of the rat metabotropic glutamate receptor type 8a revealed strong similarities and slight differences with the type 4a receptor. Eur J Pharmacol. 2000 Apr 7;394(1):17-26.
• [33] Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8.
• [34] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026877)
• [35] Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystal... J Med Chem. 2008 Jun 26;51(12):3540-54.
• [36] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 292).
• [37] Agonist analysis of 2-(carboxycyclopropyl)glycine isomers for cloned metabotropic glutamate receptor subtypes expressed in Chinese hamster ovary cells. Br J Pharmacol. 1992 Oct;107(2):539-43.
• [38] Ligand binding to the amino-terminal domain of the mGluR4 subtype of metabotropic glutamate receptor. J Biol Chem. 1999 Apr 9;274(15):10008-13.
• [39] (-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection. Neuropharmacology. 2003 Dec;45(7):895-906.
• [40] Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol. 2003 Mar;138(6):1026-30.
• [41] Synthesis and pharmacological characterization of aminocyclopentanetricarboxylic acids: new tools to discriminate between metabotropic glutamate receptor subtypes. J Med Chem. 1997 Sep 12;40(19):3119-29.